kabutan

Kringle Pharma,Inc.(4884) Summary

4884
TSE Growth
Kringle Pharma,Inc.
378
JPY
-3
(-0.79%)
Dec 12, 3:30 pm JST
2.42
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
2.12
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
381 JPY 2.45 USD
Previous Close Dec 11
381 JPY 2.44 USD
High Dec 12, 9:34 am
383 JPY 2.45 USD
Low Dec 12, 3:17 pm
378 JPY 2.42 USD
Volume
82,300
Trading Value
0.03B JPY 0.20M USD
VWAP
380.56 JPY 2.44 USD
Minimum Trading Value
37,800 JPY 242 USD
Market Cap
2.72B JPY 0.02B USD
Number of Trades
64
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
309
1-Year High Jun 12, 2025
3,785
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 957,300
Nov 28, 2025 0 948,600
Nov 21, 2025 0 937,200
Nov 14, 2025 0 906,800
Nov 7, 2025 0 921,500
Company Profile
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein.
Sector
Pharmaceuticals
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein. The company is currently conducting clinical trials for acute spinal cord injury, ALS, vocal cord scarring, and acute kidney injury. For acute spinal cord injury, a Phase III trial is in progress, aiming for a marketing authorization application. For ALS, the company is analyzing the results of a Phase II trial. A Phase III trial is underway for vocal cord scarring, while plans for the next phase of trials for acute kidney injury are being developed. Leveraging the neuroprotective and anti-fibrotic effects of HGF, Kringle Pharma aims to expand its applications to multiple intractable diseases. The company is also strengthening its new pipeline through collaborative research with universities and other companies.